OncoMatch/Clinical Trials/NCT04520074
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Is NCT04520074 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Etoposide, Cyclophosphamide, Carboplatin/Cisplatin for ovarian cancer.
Treatment: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin — Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy. There is no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. We developed an adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step) 6cycle and CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 wild-type
Required: BRCA2 wild-type
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: cytoreductive surgery
optimal cytoreductive surgery with residual tumor ≤ 1cm
Must have received: platinum-based chemotherapy (paclitaxel)
no more than 9 cycle paclitaxel + platinum chemotherapy achieved complete remission
Cannot have received: pelvic or abdominal radiotherapy
Receipt of pelvic or abdominal radiotherapy
Cannot have received: investigational medicinal product
Receipt of any other investigational medicinal product within the last 30 days before randomization
Lab requirements
Blood counts
Hemoglobin ≥9 g/dL; White blood cell count ≥3.0 × 10^9/L; Absolute neutrophil count ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L
Kidney function
Creatinine <1.5 × ULN
Liver function
AST (SGOT)/ALT (SGPT) ≤2.5 ULN; Bilirubin <1.5 × ULN
Adequate bone marrow and hepatic function at Screening: * Hemoglobin ≥9 g/dL * White blood cell count ≥3.0 × 10^9/L * Absolute neutrophil count ≥1.5 × 10^9/L * Platelet count ≥100 × 10^9/L * AST (SGOT)/ALT (SGPT) ≤2.5 ULN * Bilirubin <1.5 × ULN * Creatinine <1.5 × ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04520074 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic or abdominal radiotherapy, investigational medicinal product disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 wild-type is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages